Logo Annals of Transplantation Logo Annals of Transplantation Logo Annals of Transplantation

19 September 2008

Influence of interactions between immunosuppressive drugs on therapeutic drug monitoring

Dirk R. Kuypers

Ann Transplant 2008; 13(3): 11-18 :: ID: 868532


With the emergence of more immunosuppressive drug combinations in transplantation, the number and complexity of drug interactions have increased and constitute a growing challenge for clinicians. Especially, clinically relevant immunosuppressive drug interactions require prompt identification, intensified monitoring of drug concentrations and adequate dosing responses.
The drug interaction whereby cyclosporine, as opposed to tacrolimus, inhibits the enterohepatic (re)circulation of mycophenolic acid and its inactive MPAG metabolite, will result in significantly lower dose-corrected MPA concentrations in cyclosporine-treated patients which in turn will lead to early clinical MPA underexposure in 50% of patients receiving 2 grams of MMF per day. Also, when reducing or withdrawing cyclosporine or switching to tacrolimus as alternative calcineurin-inhibitor and vice versa, this important drug interactions needs to be taken into consideration.
The combination of cyclosporine and the proliferation signal inhibitors (PSI) sirolimus and everolimus, requires dose reductions of both drugs because of a well-established synergistic drug interaction which will lead to increased nephrotoxicity when left unadjusted. Despite the observations that clinically important drug interactions between PSI and tacrolimus are apparently lacking, switching between calcineurin-inhibitors in renal recipients requires intensified monitoring of PSI concentrations.
Finally, when corticosteroid doses are substantially reduced or completely withdrawn from a tacrolimus-based immunosuppressive regimen, a moderate increase of tacrolimus concentrations will ensue, albeit without any clearly described clinical consequences.
More attention for clinically relevant immunosuppressive drug interactions is warranted in this era of tailor-made transplantation medicine whereby an increasing number of immunosuppressive drug combinations are, not uniquely, but rather sequentially used during the life course of a transplanted organ.

Keywords: Mycophenolic Acid, Mycophenolate Mofetil, Cyclosporine A, Tacrolimus, Sirolimus, Everolimus, corticosteroids, Drug Interactions, therapeutic drug monitoring

Add Comment 0 Comments

755 40

In Press

10 Nov 2023 : Original article  

Effects of Preservation of Donor Liver Gastroduodenal Artery on Post-Transplant Biliary Complications in 18...

Ann Transplant In Press; DOI:  

07 Nov 2023 : Original article  

Allogeneic Hematopoietic Stem Cell Transplantation Can Improve Prognosis of Extramedullary Infiltration Pos...

Ann Transplant In Press; DOI:  

06 Nov 2023 : Original article  

Clinical Outcomes of Administration of Rituximab for Desensitization in Liver Transplant Patients with Pref...

Ann Transplant In Press; DOI:  

06 Nov 2023 : Original article  

Short-Term Monitoring of Graft Regeneration in Partial Liver Transplantation Recipients

Ann Transplant In Press; DOI:  

Most Viewed Current Articles

24 Aug 2021 : Review article  

Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future Perspectives

DOI :10.12659/AOT.931664

Ann Transplant 2021; 26:e931664

26 Jan 2022 : Review article  

Recurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive Models

DOI :10.12659/AOT.934924

Ann Transplant 2022; 27:e934924

29 Dec 2021 : Original article  

Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...

DOI :10.12659/AOT.933588

Ann Transplant 2021; 26:e933588

15 Mar 2022 : Case report  

Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...

DOI :10.12659/AOT.935860

Ann Transplant 2022; 27:e935860

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Annals of Transplantation eISSN: 2329-0358
Annals of Transplantation eISSN: 2329-0358